This latter property can exert tumor-suppressive effects: in esophageal squamous cell carcinoma (SCC), patients with high OCTN2-expressing tumors receiving oxaliplatin-based chemotherapy demonstrate significantly better therapeutic response, reduced recurrence rates, and prolonged overall survival compared to patients with low OCTN2 expression. Here, SLC22A5 is linked to neoplasm.